A 3-year-old South Dakota boy whose brain tumor treatment had been in question because of an insurance dispute is set to begin chemotherapy in Minnesota this week.
Cooper Urbaniak, who suffers from ependymoma, is to be admitted to the University of Minnesota Medical Center Tuesday to begin high-dose chemotherapy and a stem cell transplant.
The family’s insurance provider initially declared the procedure experimental and refused to pay for it. But under an agreement reached last month between Sanford Health Plan and the university, Sanford will pay for the chemotherapy and pay a discounted rate on the stem cell transplant.
Cooper’s father, Joe
Two scientists at the Fred Hutchinson Cancer Research Center in Seattle have been awarded $16.7 million for stem cell research projects.
Dr. Irwin Bernstein and Beverly Torok-Storb received the federal funding from the National Heart, Lung and Blood Institute. Their award is part of a $170 million effort divided among 18 scientific teams.
Torok-Storb will work with Dr. Mortimer Poncz of Children’s Hospital of Philadelphia to develop molecular and cell-based therapies for a range of blood diseases, using an $8.2 million grant.
Bernstein will work with Edward Morrisey of the University of Pennsylvania to study how biochemical reactions inside cells affect cell
The Jumonjd3 protein is a sort of nervous system regulator, allowing stem cells to become neural cells. Researchers from the IFOM-IEO Campus of the European Institute of Oncology (EIO) in Milan, whose studies were published in Plos One magazine discovered the regulator protein. The researchers explained that the protein is an enzyme capable of activating the stem cell genes necessary to differentiate a cell into a nervous system cell.
The result, underlined the scientists led by Giusepe Testa, “adds an important perspective to understanding the intricate mechanisms of stem cell function.” This protein could soon become “a target to improve
In what could be a major breakthrough in fighting prostate cancer, a researcher from Gitam Institute of Technology (GIT) has found that a drug used for treating coronary heart disease and stroke can control the progression of this form of cancer.
Prostate cancer develops in the prostate, a gland in the male reproductive system, and is said to be among the top three types of cancers afflicting men apart from lung and gastric cancers. Patients suffering from prostate cancer have difficulty in urinating, feel the need to frequently pass urine and experience pain when passing urine.
Although a growing number of people today are stricken with cancer – the leading cause of death in France since 2004 – their risk of succumbing to this disease is dropping. Nationwide mortality rates continue to vary, most notably on a regional level, as was demonstrated in the distinguished Atlas de la mortalité par cancer en France metropolitaine [Atlas of cancer death in mainland France (excluding overseas territories)], published on January 28. On a generalized basis, the numbers for Northern and Central France clearly point to hypermortality while death rates in the southern portion of the country were lower